基于全血细胞计数预测骨髓纤维化:多中心机器学习模型FIBOM-AI的开发与验证
该研究利用13家法国大学医院的回顾性数据开发了FIBOM-AI模型,以27项全血细胞计数变量和年龄预测骨髓增殖性肿瘤患者2-3级骨髓纤维化。
要点
- 该工具可作为分诊和优先级排序工具,辅助及时骨髓评估或补充风险评估。
核心结论
- FIBOM-AI可可靠地用作分诊和优先级排序工具,支持及时骨髓评估或在骨髓活检不可立即进行时提供补充风险评估。
研究设计与样本
- 使用27项全血细胞计数变量和活检时年龄作为预测因子,9种算法经10折交叉验证训练,以2-3级纤维化为二分类终点。
关键数值与推荐
- 最终模型设定两种预测:总体预测最大化整体准确率,自信预测最大化敏感性(排除)或特异性(确认)。
临床怎么用
- FIBOM-AI可作为分诊和优先级排序工具,帮助确定骨髓评估的及时性。
- 当骨髓活检不能立即进行时,该模型可提供补充性风险评估。
局限性
- 回顾性数据收集可能引入选择偏倚。
- 前瞻性验证仅纳入5家中心,外部泛化性需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bone marrow biopsy is essential for myeloproliferative neoplasms diagnosis, particularly for assessing bone marrow fibrosis. However, it is an invasive procedure that can be difficult to perform in some patients. This study aimed to develop an artificial intelligence (AI) model (FIBOM-AI) to predict grade 2-3 fibrosis using complete blood count (CBC) data and age. METHODS: In this machine learning model, histopathological and CBC data from patients (no age restriction) undergoing bone marrow biopsies, performed either at diagnosis or during follow-up for suspected or established myeloproliferative neoplasm, were retrospectively collected across 13 French university hospitals. 27 CBC variables and patient age at biopsy were used as predictors. Data from six independent centres were used for model development and the remaining seven centres were used for external validation. The primary outcome was grade 2-3 fibrosis as a binary endpoint. Nine algorithms were trained using 10-fold cross validation. The final model was evaluated in a real-life prospective setting on all bone marrow biopsies performed in four French centres and one Canadian centre. To guide clinical decisions, two different predictions based on the final model were set: an overall prediction, maximising the overall accuracy of the model, and a confident prediction, maximising either sensitivity (rule-out) or specificity (rule-in). FINDINGS: Between Jan 1, 2014, and Dec 31, 2023, 1995 patients from 13 centres were included in the retrospective cohort; the median age was 62·0 years (IQR 50·0-71·0), 1062 (53·2%) were male, and 933 (46·8%) were female. Between Jan 1, 2024, and Dec 31, 2024, 493 patients from five centres were included in the prospective cohort; the median age was 65·0 years (IQR 53·6-73·0), 297 (60·2%) were male, and 196 (39·8%) were female. The Extreme Gradient Boosting model had the best performance, with an area under the curve of 0·96 (95% CI 0·95-0·97), 0·90 (0·85-0·95), and 0·92 (0·90-0·95) on the training, testing, and validation sets, respectively. The final accuracy was 88·1%, 87·0%, and 88·6% for the overall predictions and 99·5%, 94·5%, and 96·9% for the confident predictions in the training, testing, and validation sets, respectively. Prospective evaluation showed an accuracy of 85·2% (range 82·0-87·3) for the overall predictions and 98·6% (96·0-100·0) for the confident predictions. INTERPRETATION: FIBOM-AI can be reliably used as a triage and prioritisation tool to support timely bone marrow evaluation or provide complementary risk assessment when bone marrow biopsy is not immediately feasible. FUNDING: None.
引用
- Donzel M, Khedimallah S, Barriere S, et al. Prediction of bone marrow fibrosis from complete blood count in myeloproliferative neoplasms (FIBOM-AI): a multicentre machine learning model development and validation study. Lancet Haematol. 2026. PMID: 42242261. doi:10.1016/S2352-3026(26)00099-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。